From today, adults with advanced Hodgkin lymphoma have access to a new treatment, after we recommended brentuximab vedotin (brand name Adcetris) in combination with other therapies for routine NHS use ...

Around 5,000 blood cancer patients could benefit from 13 treatments recommended by NICE in 2024. This is the largest number of positive recommendations in a single year for blood cancer treatments.

Our chief medical officer, Professor Jonathan Benger, explains the crucial role the HST programme plays in encouraging ...

As set out in the NHS Commercial Framework for New Medicines, a commercial access agreement (CAA) is a complex confidential agreement and is agreed at NHS England’s discretion. A CAA proposal can only ...